Novartis Pelacarsen Trial Fails: What the Lp(a) Setback Means for Traders

Novartis has seen its heavily watched cholesterol-related drug pelacarsen fail to cut heart attacks, strokes and other serious events in the full Phase 3 results, presented on Saturday at the American Heart Association meeting. The drug had been seen as a potential blockbuster, so the outcome matters for anyone who follows large-cap pharma, the wider healthcare sector, and the race to develop treatments aimed at lipoprotein(a), or Lp(a).

Key takeaways

• Pelacarsen lowered Lp(a) sharply but did not reduce major cardiovascular events versus placebo in the Lp(a)HORIZON trial.
• Novartis first flagged the miss in top-line results on 4 September, so the headline outcome was not new to the market.
• A related Novartis study has been withdrawn following the result, according to the ClinicalTrials.gov registry.
• The big US tech names in our snapshot are moving on other themes, with no direct link to this story.

What the trial found

The trial enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease. Participants were randomly assigned to a monthly injection of pelacarsen or a placebo. The American Heart Association reported that pelacarsen reduced Lp(a) significantly, by an average of 78% across all participant groups.

Despite that, the clinical benefit did not appear. According to STAT News, the trial showed no difference in heart attacks, strokes, urgent coronary revascularization, or deaths in participants followed for almost five years. NBC News reported that the trial's leader, Steven Nissen, said the results took him by "extreme surprise."

Background: why the drug mattered

Lp(a) is a genetic risk factor. STAT notes that it is carried by 1 in 5 people and is the target of a growing group of experimental therapies. Pelacarsen was developed by Novartis together with Ionis Pharmaceuticals, and Lp(a)HORIZON was the pivotal outcomes study, so investors treated it as a test of the whole approach.

Researchers have offered possible explanations. One suggestion is that short-term Lp(a) reduction may not confer the benefit linked to lifelong lower levels seen in genetic studies, and that tight control of other risk factors may have limited any added benefit. Experts also stress that Lp(a) remains an important indicator of heart disease risk, even though lowering it did not help here.

Pipeline fallout and market context

The setback has already reached the pipeline. ClinicalTrials.gov lists a separate US pelacarsen study in patients with recent acute coronary syndrome as withdrawn, noting that the sponsor terminated it following the outcome of the Lp(a)HORIZON study.

On the market side, Saturday is a weekend, so the figures in our 15:26 UTC snapshot reflect the latest session quotes rather than live trading. None of the large US names we track is directly tied to this story. NVIDIA was at 186.64 (+2.78%), Microsoft at 530.61 (-0.99%), Apple at 342.37 (-0.52%) and Tesla at 358.22 (+4.23%). Taiwan Semiconductor stood at 375.44 (+6.33%). Those moves point to technology and chip themes driving sentiment, not healthcare.

What to watch next

• How Novartis and Ionis describe the drug's future, and whether further analyses of the data change the picture.
• Whether rival Lp(a)-lowering programs face tougher scrutiny from regulators, doctors and investors.
• How Novartis shares trade when European markets reopen, given that the top-line miss was announced earlier.
• Any commentary on whether other drug mechanisms for lowering Lp(a) might behave differently.

For traders, trial failures are a reminder that single-asset binary events can swing pharma valuations, which is why many market participants size positions cautiously around data releases.

Markets are volatile and this article is educational content, not investment advice.